Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

Similar articles for PubMed (Select 20097678)

1.

Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression.

Pouladi MA, Xie Y, Skotte NH, Ehrnhoefer DE, Graham RK, Kim JE, Bissada N, Yang XW, Paganetti P, Friedlander RM, Leavitt BR, Hayden MR.

Hum Mol Genet. 2010 Apr 15;19(8):1528-38. doi: 10.1093/hmg/ddq026. Epub 2010 Jan 22.

2.

Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.

Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I.

Neurobiol Dis. 2008 Jul;31(1):80-8. doi: 10.1016/j.nbd.2008.03.010. Epub 2008 Apr 16.

3.
4.

Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.

Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR.

Hum Mol Genet. 2005 Dec 15;14(24):3823-35. Epub 2005 Nov 8.

5.

Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.

Cowan CM, Fan MM, Fan J, Shehadeh J, Zhang LY, Graham RK, Hayden MR, Raymond LA.

J Neurosci. 2008 Nov 26;28(48):12725-35. doi: 10.1523/JNEUROSCI.4619-08.2008.

6.

Selective degeneration in YAC mouse models of Huntington disease.

Van Raamsdonk JM, Warby SC, Hayden MR.

Brain Res Bull. 2007 Apr 30;72(2-3):124-31. Epub 2006 Nov 16. Review.

PMID:
17352936
7.

Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice.

Gray M, Shirasaki DI, Cepeda C, André VM, Wilburn B, Lu XH, Tao J, Yamazaki I, Li SH, Sun YE, Li XJ, Levine MS, Yang XW.

J Neurosci. 2008 Jun 11;28(24):6182-95. doi: 10.1523/JNEUROSCI.0857-08.2008.

8.

P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.

Fan J, Gladding CM, Wang L, Zhang LY, Kaufman AM, Milnerwood AJ, Raymond LA.

Neurobiol Dis. 2012 Mar;45(3):999-1009. doi: 10.1016/j.nbd.2011.12.019. Epub 2011 Dec 14.

PMID:
22198502
9.

Body weight is modulated by levels of full-length huntingtin.

Van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR, Hayden MR.

Hum Mol Genet. 2006 May 1;15(9):1513-23. Epub 2006 Mar 28.

10.

Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease.

Van Raamsdonk JM, Pearson J, Rogers DA, Bissada N, Vogl AW, Hayden MR, Leavitt BR.

Hum Mol Genet. 2005 May 15;14(10):1379-92. Epub 2005 Apr 13.

11.

Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.

Chan EY, Luthi-Carter R, Strand A, Solano SM, Hanson SA, DeJohn MM, Kooperberg C, Chase KO, DiFiglia M, Young AB, Leavitt BR, Cha JH, Aronin N, Hayden MR, Olson JM.

Hum Mol Genet. 2002 Aug 15;11(17):1939-51.

12.

Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation.

Valenza M, Carroll JB, Leoni V, Bertram LN, Björkhem I, Singaraja RR, Di Donato S, Lutjohann D, Hayden MR, Cattaneo E.

Hum Mol Genet. 2007 Sep 15;16(18):2187-98. Epub 2007 Jul 5.

13.

Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.

Tanaka Y, Igarashi S, Nakamura M, Gafni J, Torcassi C, Schilling G, Crippen D, Wood JD, Sawa A, Jenkins NA, Copeland NG, Borchelt DR, Ross CA, Ellerby LM.

Neurobiol Dis. 2006 Feb;21(2):381-91. Epub 2005 Sep 16.

PMID:
16150600
14.

Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.

Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE, Hackam AS, Logvinova AV, Peel AL, Chen SF, Hook V, Singaraja R, Krajewski S, Goldsmith PC, Ellerby HM, Hayden MR, Bredesen DE, Ellerby LM.

Cell Death Differ. 2004 Apr;11(4):424-38.

15.

Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A.

Metzler M, Gan L, Mazarei G, Graham RK, Liu L, Bissada N, Lu G, Leavitt BR, Hayden MR.

J Neurosci. 2010 Oct 27;30(43):14318-29. doi: 10.1523/JNEUROSCI.1589-10.2010.

17.

Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease.

Fan J, Cowan CM, Zhang LY, Hayden MR, Raymond LA.

J Neurosci. 2009 Sep 2;29(35):10928-38. doi: 10.1523/JNEUROSCI.2491-09.2009.

18.

IGF-1 protects against diabetic features in an in vivo model of Huntington's disease.

Duarte AI, Petit GH, Ranganathan S, Li JY, Oliveira CR, Brundin P, Björkqvist M, Rego AC.

Exp Neurol. 2011 Oct;231(2):314-9. doi: 10.1016/j.expneurol.2011.06.016. Epub 2011 Jul 7.

PMID:
21763311
19.

A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.

Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR.

Neuron. 1999 May;23(1):181-92.

20.

Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.

Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, Pearson J, Vaid K, Bissada N, Wetzel R, Leavitt BR, Hayden MR.

Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11402-7. Epub 2005 Aug 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk